SEC Form 1-Z filed by Scopus BioPharma Inc.
Form 1-Z Issuer Information |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 1-Z EXIT REPORT UNDER REGULATION A | OMB APPROVAL |
| OMB Number: 3235-0723 Estimated average burden hours per response: 1.5 |
1-Z: Filer Information
Issuer CIK | 0001772028 |
Issuer CCC | XXXXXXXX |
File Number | |
Is this filing by a successor company pursuant to Rule 257(b)(5) resulting from a merger or other business combination? | Yes No |
Successor File Number |
Is this a LIVE or TEST Filing? | LIVE TEST |
Is this an electronic copy of an official filing submitted in paper format? | |
Would you like a Return Copy? |
Submission Contact Information
Name | |
Phone | |
E-Mail Address |
Notify via Filing Website only? |
1-Z: PRELIMINARY INFORMATION
Exact name of issuer as specified in the issuer's charter | Scopus BioPharma Inc. |
Address of Principal Executive Offices | |
Address 1 | 420 LEXINGTON AVENUE, SUITE 300 |
Address 2 | |
City | NEW YORK |
State/Country |
NEW YORK
|
Mailing Zip/ Postal Code | 10170 |
Phone | 212-479-2513 |
Commission File Number(s) | 024-11137 |
Commission File Number(s) | 024-11228 |
1-Z: PART II Certification of Suspension of Duty to File Reports
Certification
Title of each class of securities covered by this Form | Series A Units; Common Stock, par value $0.001 per share |
Commission File Number(s) | 024-11137 |
Commission File Number(s) | 024-11228 |
Approximate number of holders of record as of the certification date | 251 |
1-Z: Signature
Signature
Pursuant to the requirements of Regulation A,
Cik | 0001772028 |
(Name of issuer as specified in charter) | Scopus BioPharma Inc. |
certifies that it meets all of the conditions for termination of Regulation A reporting specified in Rule 257(d) and that there are no classes of securities other than those that are the subject to this Form 1-Z regarding which the issuer has Regulation A reporting obligations.
(Name of issuer as specified in charter) | Scopus BioPharma Inc. |
Has caused this certification to be signed on its behalf by the undersigned duly authorized person.
By | /s/ Joshua R. Lamstein |
Date | 02-09-2024 |
Title | Chairman |